CN111808817A - 一种骨肉瘤类器官的培养方法及其骨肿瘤培养基 - Google Patents
一种骨肉瘤类器官的培养方法及其骨肿瘤培养基 Download PDFInfo
- Publication number
- CN111808817A CN111808817A CN202010724009.2A CN202010724009A CN111808817A CN 111808817 A CN111808817 A CN 111808817A CN 202010724009 A CN202010724009 A CN 202010724009A CN 111808817 A CN111808817 A CN 111808817A
- Authority
- CN
- China
- Prior art keywords
- culture
- osteosarcoma
- culture medium
- organoid
- minutes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000018084 Bone neoplasm Diseases 0.000 title claims abstract description 52
- 239000001963 growth medium Substances 0.000 title claims abstract description 46
- 201000008968 osteosarcoma Diseases 0.000 title claims abstract description 40
- 238000012136 culture method Methods 0.000 title claims abstract description 12
- 210000000056 organ Anatomy 0.000 title description 6
- 210000002220 organoid Anatomy 0.000 claims abstract description 53
- 102000008186 Collagen Human genes 0.000 claims abstract description 45
- 108010035532 Collagen Proteins 0.000 claims abstract description 45
- 229920001436 collagen Polymers 0.000 claims abstract description 45
- 210000001519 tissue Anatomy 0.000 claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 230000029087 digestion Effects 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 12
- 230000001079 digestive effect Effects 0.000 claims abstract description 11
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 11
- 238000009630 liquid culture Methods 0.000 claims abstract description 9
- 108010024636 Glutathione Proteins 0.000 claims abstract description 6
- 238000004140 cleaning Methods 0.000 claims abstract description 6
- 238000005520 cutting process Methods 0.000 claims abstract description 6
- 238000001914 filtration Methods 0.000 claims abstract description 6
- 229960003180 glutathione Drugs 0.000 claims abstract description 6
- 238000007747 plating Methods 0.000 claims abstract description 6
- 239000000725 suspension Substances 0.000 claims abstract description 6
- 238000005406 washing Methods 0.000 claims abstract description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 239000002609 medium Substances 0.000 claims description 18
- 239000011159 matrix material Substances 0.000 claims description 15
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 12
- 230000005012 migration Effects 0.000 claims description 12
- 238000013508 migration Methods 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000007853 buffer solution Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000003636 conditioned culture medium Substances 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000005119 centrifugation Methods 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 3
- 102000029816 Collagenase Human genes 0.000 claims description 3
- 108060005980 Collagenase Proteins 0.000 claims description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 3
- 239000007995 HEPES buffer Substances 0.000 claims description 3
- 102000044880 Wnt3A Human genes 0.000 claims description 3
- 108700013515 Wnt3A Proteins 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 3
- 230000001112 coagulating effect Effects 0.000 claims description 3
- 229960002424 collagenase Drugs 0.000 claims description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 239000008223 sterile water Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 30
- 230000003902 lesion Effects 0.000 description 5
- 206010005949 Bone cancer Diseases 0.000 description 4
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 102000006835 Lamins Human genes 0.000 description 3
- 108010047294 Lamins Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 210000005053 lamin Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 201000007327 bone benign neoplasm Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/345—Gastrin; Cholecystokinins [CCK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
- C12N2509/10—Mechanical dissociation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010724009.2A CN111808817B (zh) | 2020-07-24 | 2020-07-24 | 一种骨肉瘤类器官的培养方法及其骨肿瘤培养基 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010724009.2A CN111808817B (zh) | 2020-07-24 | 2020-07-24 | 一种骨肉瘤类器官的培养方法及其骨肿瘤培养基 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111808817A true CN111808817A (zh) | 2020-10-23 |
CN111808817B CN111808817B (zh) | 2024-07-19 |
Family
ID=72861164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010724009.2A Active CN111808817B (zh) | 2020-07-24 | 2020-07-24 | 一种骨肉瘤类器官的培养方法及其骨肿瘤培养基 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111808817B (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113073080A (zh) * | 2021-06-03 | 2021-07-06 | 北京科途医学科技有限公司 | 一种多形性横纹肌肉瘤类器官及其培养方法、培养基和用途 |
CN113106066A (zh) * | 2021-05-13 | 2021-07-13 | 杭州艾名医学科技有限公司 | 一种肉瘤细胞培养基以及采用该培养基体外生产Matrigel原液的方法 |
CN113186163A (zh) * | 2021-01-18 | 2021-07-30 | 南昌五元生物科技有限公司 | 一种基于p53突变筛选肿瘤类器官的培养方法 |
CN114921413A (zh) * | 2022-05-31 | 2022-08-19 | 创芯国际生物科技(广州)有限公司 | 一种骨肉瘤类器官培养基及培养方法 |
CN115651909A (zh) * | 2022-07-14 | 2023-01-31 | 上海交通大学医学院附属第九人民医院 | 一种骨肉瘤类器官模型、构建方法及应用 |
CN115851577A (zh) * | 2022-12-23 | 2023-03-28 | 北京市创伤骨科研究所 | 一种基于单细胞的骨肉瘤类器官模型的构建方法 |
CN116836934A (zh) * | 2023-08-31 | 2023-10-03 | 北京大橡科技有限公司 | 骨肉瘤类器官培养液、培养试剂组合及培养方法 |
CN117701505A (zh) * | 2024-02-06 | 2024-03-15 | 山东伯桢生物科技有限公司 | 肉瘤组织类器官培养基、构建肉瘤组织类器官和肉瘤组织类器官库的方法、构建动物疾病模型的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105770992A (zh) * | 2016-03-11 | 2016-07-20 | 刘向伟 | 一种表面预成骨种植体及其制备方法 |
CN109609461A (zh) * | 2018-12-26 | 2019-04-12 | 中国人民解放军第二军医大学第二附属医院 | 一种原代肿瘤细胞分离培养方法 |
CN109679915A (zh) * | 2019-02-27 | 2019-04-26 | 南方医科大学南方医院 | 一种鼻咽癌类器官的培养与鉴定方法 |
CN110475860A (zh) * | 2017-03-16 | 2019-11-19 | 美迪恩斯生命科技株式会社 | 使用肿瘤组织的原代癌细胞的三维培养 |
CN110656086A (zh) * | 2019-10-11 | 2020-01-07 | 纳肽得(青岛)生物医药有限公司 | 癌类器官的体外培养方法 |
-
2020
- 2020-07-24 CN CN202010724009.2A patent/CN111808817B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105770992A (zh) * | 2016-03-11 | 2016-07-20 | 刘向伟 | 一种表面预成骨种植体及其制备方法 |
CN110475860A (zh) * | 2017-03-16 | 2019-11-19 | 美迪恩斯生命科技株式会社 | 使用肿瘤组织的原代癌细胞的三维培养 |
US20200071676A1 (en) * | 2017-03-16 | 2020-03-05 | Lsi Medience Corporation | Three-dimensional culture of primary cancer cells using tumor tissue |
CN109609461A (zh) * | 2018-12-26 | 2019-04-12 | 中国人民解放军第二军医大学第二附属医院 | 一种原代肿瘤细胞分离培养方法 |
CN109679915A (zh) * | 2019-02-27 | 2019-04-26 | 南方医科大学南方医院 | 一种鼻咽癌类器官的培养与鉴定方法 |
CN110656086A (zh) * | 2019-10-11 | 2020-01-07 | 纳肽得(青岛)生物医药有限公司 | 癌类器官的体外培养方法 |
Non-Patent Citations (2)
Title |
---|
JAMES T. NEAL等: "Organoid Modeling of the Tumor Immune" * |
JARNO DROST等: "Organoid culture systems for prostate epithelial and cancer tissue" * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113186163A (zh) * | 2021-01-18 | 2021-07-30 | 南昌五元生物科技有限公司 | 一种基于p53突变筛选肿瘤类器官的培养方法 |
CN113106066A (zh) * | 2021-05-13 | 2021-07-13 | 杭州艾名医学科技有限公司 | 一种肉瘤细胞培养基以及采用该培养基体外生产Matrigel原液的方法 |
CN113106066B (zh) * | 2021-05-13 | 2022-08-23 | 杭州艾名医学科技有限公司 | 一种肉瘤细胞培养基以及采用该培养基体外生产Matrigel原液的方法 |
CN113073080A (zh) * | 2021-06-03 | 2021-07-06 | 北京科途医学科技有限公司 | 一种多形性横纹肌肉瘤类器官及其培养方法、培养基和用途 |
CN113073080B (zh) * | 2021-06-03 | 2021-08-13 | 北京科途医学科技有限公司 | 一种多形性横纹肌肉瘤类器官及其培养方法、培养基和用途 |
CN114921413A (zh) * | 2022-05-31 | 2022-08-19 | 创芯国际生物科技(广州)有限公司 | 一种骨肉瘤类器官培养基及培养方法 |
CN115651909A (zh) * | 2022-07-14 | 2023-01-31 | 上海交通大学医学院附属第九人民医院 | 一种骨肉瘤类器官模型、构建方法及应用 |
CN115651909B (zh) * | 2022-07-14 | 2023-09-19 | 上海交通大学医学院附属第九人民医院 | 一种骨肉瘤类器官模型、构建方法及应用 |
WO2024012073A1 (zh) * | 2022-07-14 | 2024-01-18 | 上海交通大学医学院附属第九人民医院 | 一种骨肉瘤类器官模型、构建方法及应用 |
CN115851577A (zh) * | 2022-12-23 | 2023-03-28 | 北京市创伤骨科研究所 | 一种基于单细胞的骨肉瘤类器官模型的构建方法 |
CN116836934A (zh) * | 2023-08-31 | 2023-10-03 | 北京大橡科技有限公司 | 骨肉瘤类器官培养液、培养试剂组合及培养方法 |
CN116836934B (zh) * | 2023-08-31 | 2023-11-24 | 北京大橡科技有限公司 | 骨肉瘤类器官培养液、培养试剂组合及培养方法 |
CN117701505A (zh) * | 2024-02-06 | 2024-03-15 | 山东伯桢生物科技有限公司 | 肉瘤组织类器官培养基、构建肉瘤组织类器官和肉瘤组织类器官库的方法、构建动物疾病模型的方法 |
CN117701505B (zh) * | 2024-02-06 | 2024-06-11 | 山东伯桢生物科技有限公司 | 肉瘤组织类器官培养基、构建肉瘤组织类器官和肉瘤组织类器官库的方法、构建动物疾病模型的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN111808817B (zh) | 2024-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111808817A (zh) | 一种骨肉瘤类器官的培养方法及其骨肿瘤培养基 | |
Hu et al. | Biologic properties of three newly established human esophageal carcinoma cell lines | |
KR101722033B1 (ko) | 소변으로부터의 전구 세포 및 이를 사용하는 방법 | |
An et al. | Development of a high metastatic orthotopic model of human renal cell carcinoma in nude mice: benefits of fragment implantation compared to cell-suspension injection | |
CN106974938B (zh) | 一种具有抗肝癌作用的骨髓间充质干细胞来源的外泌体及其药物制剂 | |
CN103865876A (zh) | 一种肿瘤细胞原代培养的方法 | |
JPH11501656A (ja) | 腫瘍を処置する方法 | |
CN113293133B (zh) | 一种人乳腺恶性叶状肿瘤细胞株及其应用 | |
CN113136364B (zh) | 一种壁蜕膜间充质干细胞的制备方法、复苏方法 | |
CN113308437B (zh) | 用于快速培养骨转移癌类器官的培养基、方法以及试剂盒 | |
CN106943432B (zh) | 一种脐带间充质干细胞来源的外泌体及其在制备治疗肝癌药物中的应用 | |
CN112430567A (zh) | 一种尿源性肾干细胞的培养方法及其应用 | |
CN114717190B (zh) | 一种人乳腺恶性叶状肿瘤细胞系bpt0713及其应用 | |
Cobb | The behaviour of carcinoma of the large bowel in man following transplantation into immune deprived mice | |
CN114075539B (zh) | 构建原位原发膀胱癌动物模型的方法 | |
CN111961640A (zh) | 一种尿源性肾干细胞三维分化模型的构建方法及培养体系 | |
CN113667645A (zh) | 一种犬乳腺癌细胞系、其建立方法及应用 | |
US20110206735A1 (en) | Tumorigenic CancerStemCells, Methods of Isolating and Using the Same | |
CN115851577A (zh) | 一种基于单细胞的骨肉瘤类器官模型的构建方法 | |
CN115386542B (zh) | 工程化的鹿茸干细胞外泌体和制备方法、及在骨肉瘤治疗中的应用 | |
CN116970554A (zh) | 一种肺动脉平滑肌肉瘤细胞系及其制备方法和应用 | |
CN113801849B (zh) | 一种人乳腺良性叶状肿瘤细胞株bpt-0526及其应用 | |
CN112300996B (zh) | 一种脑胶质瘤类器官的3d培养基及其应用 | |
CN110396501B (zh) | 一种体外维持乳腺癌干细胞干性的三维球形体培养方法 | |
JP2019534041A (ja) | がん幹細胞(csc)増大のための方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240905 Address after: Room 605, 6th Floor, Building 02, Life Science and Technology Island, No. 11 Yaogu Avenue, Jiangbei New District, Nanjing City, Jiangsu Province, China 210000 Patentee after: Nanjing Zewei Biotechnology Co.,Ltd. Country or region after: China Address before: Block B, 4 / F, No. 13, Lane 1199, JiZhai Road, Minhang District, Shanghai, 201107 Patentee before: Shanghai Haobai Biotechnology Co.,Ltd. Country or region before: China |